The group is recognized for developing quantitative assays to detect exposure to COVID-19 and strengthen the rapid response to the ongoing pandemic. In 9 months, the group established NIST as a leader in interagency coordination and global standards development; produced antibody assays to underpin global diagnostics, disease monitoring, and vaccine development; and enabled the development of World Health Organization reference materials distributed worldwide. The group’s efforts directly support accurate clinical tests for COVID-19 today and for potential future pandemics.